XOMA Corporation (XOMA)
NASDAQ: XOMA · IEX Real-Time Price · USD
28.06
+0.65 (2.37%)
At close: Jul 19, 2024, 4:30 PM
28.10
+0.04 (0.14%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
XOMA Corporation Market Cap
XOMA Corporation has a market cap or net worth of $326.58 million as of July 22, 2024. Its market cap has increased by 73.99% in one year.
Market Cap
326.58M
Enterprise Value
310.83M
1-Year Change
73.99%
Ranking
Category
Stock Price
$28.06
Market Cap Chart
Since December 1, 1998, XOMA Corporation's market cap has increased from $151.40M to $326.58M, an increase of 115.71%. That is a compound annual growth rate of 3.04%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
Jul 19, 2024 | 326.60M | 53.69% |
Dec 29, 2023 | 212.50M | 0.85% |
Dec 30, 2022 | 210.70M | -10.64% |
Dec 31, 2021 | 235.80M | -51.52% |
Dec 31, 2020 | 486.40M | 103.60% |
Dec 31, 2019 | 238.90M | 125.16% |
Dec 31, 2018 | 106.10M | -63.40% |
Dec 29, 2017 | 289.90M | 1,036.86% |
Dec 30, 2016 | 25.50M | -83.86% |
Dec 31, 2015 | 158.00M | -59.01% |
Dec 31, 2014 | 385.50M | -38.46% |
Dec 31, 2013 | 626.40M | 220.08% |
Dec 31, 2012 | 195.70M | 396.70% |
Dec 30, 2011 | 39.40M | -64.76% |
Dec 31, 2010 | 111.80M | -19.57% |
Dec 31, 2009 | 139.00M | 69.31% |
Dec 31, 2008 | 82.10M | -81.63% |
Dec 31, 2007 | 447.00M | 100.18% |
Dec 29, 2006 | 223.30M | 61.69% |
Dec 30, 2005 | 138.10M | -37.68% |
Dec 31, 2004 | 221.60M | -59.61% |
Dec 31, 2003 | 548.60M | 84.40% |
Dec 31, 2002 | 297.50M | -56.92% |
Dec 31, 2001 | 690.50M | 7.32% |
Dec 29, 2000 | 643.40M | 285.96% |
View and export this data all the way back to 1998.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Nevro | 334.23M |
Kamada | 332.20M |
ADC Therapeutics | 331.02M |
Inozyme Pharma | 329.69M |
Nautilus Biotechnology | 326.94M |
Foghorn Therapeutics | 326.44M |
Spok Holdings | 325.55M |
Black Diamond Therapeutics | 323.45M |